The change in total lesion glycolysis measured prior to and after two cycles of chemotherapy provided a better prediction of response to chemotherapy than other PET measures, including change in standardized uptake value, according to a study published online Jan. 17 in The Journal of Nuclear Medicine.

RSNA has released official registration figures for its 2012 annual meeting, and reported total registration was 53,778—9 percent lower overall than in 2011.

New methods for PET/CT imaging are being developed for imaging cancer patients without overexposing them to radiation while also guaranteeing excellent image quality.

Timely and accurate diagnosis and treatment of infection in post-transplant organ patients is critical to patient survival and the prevention of organ rejection. 

 Nuclear cardiology is on the dawn of a new technology—IQ•SPECT promises to reduce acquisition time, add hybrid or fusion imaging with CT and maximize efficiency in SPECT/CT scanning.

Initial Results from National Oncologic PET Registry (NOPR) have been published recently in the Journal of Clinical Oncology. The results provide impressive evidence for the substantial impact of PET imaging across all cancers.

Evidence-based medicine has been embraced as a practice to increase healthcare expenditures and as a tool to improve patient care, ensuring that patients receive the best resources for their care, without unnecessary and wasteful procedures. Clinical results are proving molecular imaging’s merits in a wider number of applications. 

The overall cancer mortality rate fell 20 percent between its peak in 1991 and 2009, translating to the avoidance of approximately 1.2 million cancer deaths, according to the American Cancer Society’s (ACS) annual reporting of cancer statistics. The Medical Imaging & Technology Alliance (MITA) acknowledged the progress and called for Medicare coverage of CT screening for colon and lung cancer.